Related Experiment Video

Updated: Jul 25, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Emerging antibody-based HER2 (ErbB-2/neu) therapeutics

W C Krauss1, J W Park, D B Kirpotin

  • 1Department of Medicine, Division of Hematology-Oncology, University of California, San Francisco, San Francisco, CA 94143-1270, USA.

Breast Disease
|February 3, 2005
PubMed

Insights

Targeting HER2-overexpressing cancers with antibody-based therapies, like anti-HER2 immunoliposomes delivering doxorubicin, shows superior efficacy. This approach promises reduced toxicity and broader applications for novel drug delivery in cancer treatment.

Area of Science:

  • Oncology
  • Nanotechnology
  • Pharmacology

Background:

  • HER2 receptor tyrosine kinase is a key target in breast and epithelial cancers.
  • Antibody-based therapeutics targeting HER2 include monoclonal antibodies, immunotoxins, and bispecific antibodies.
  • Selective delivery of anticancer agents to HER2-overexpressing tumor cells can reduce host toxicity.

Purpose of the Study:

  • To review advances in antibody-based HER2-targeting strategies.
  • To focus on preclinical development of anti-HER2 immunoliposomes (ILs) for targeted drug delivery.
  • To evaluate the therapeutic efficacy of anti-HER2 ILs-doxorubicin (dox).

Main Methods:

  • Review of recent advances in antibody-based HER2-targeting strategies.
  • Preclinical development and testing of anti-HER2 immunoliposomes (ILs).
  • In vitro and in vivo efficacy and tumor uptake studies in human tumor xenograft models.

Main Results:

  • Anti-HER2 ILs-doxorubicin demonstrated superior therapeutic efficacy compared to free doxorubicin or liposomal doxorubicin.
  • Anti-HER2 ILs-doxorubicin showed greater efficacy than combinations of doxorubicin, liposomal doxorubicin, and rhuMAbHER2.
  • Extensive preclinical data support the effectiveness of anti-HER2 ILs-doxorubicin.

Conclusions:

  • Anti-HER2 immunoliposomes represent a promising platform technology for targeted anticancer drug delivery.
  • Anti-HER2 ILs-doxorubicin are approaching clinical testing for advanced HER2-overexpressing breast cancer.
  • Future applications include intracellular delivery of other anticancer agents and therapeutic nucleic acids.

More Related Videos

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells08:28

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...